The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.

The firm's share price fell after a presentation at the conference revealed lower-than-expected Elevidys sales.

The company is also anticipating new data on its antibody-drug conjugate Trodelvy in PD-L1-high non-small cell lung cancer ...

The company highlighted multiple myeloma and CAR T therapies as growth drivers and announced two new US manufacturing ...

NEW YORK – The European Commission has approved a high-dose regimen of Biogen's Spinraza (nusinersen), an antisense oligonucleotide for 5q spinal muscular atrophy (SMA).

Since its US, Japan, and China approvals, the ROS1-positive NSCLC drug recorded $15.7 million and $24.7 million in revenue in Q4 and full-year 2025, respectively.

The agency is asking the firm to conduct a new study, which Pierre Fabre says is "a significant and unexpected change" from prior discussions.

The company plans to begin a registrational trial of a GPC3-targeted cell therapy for hepatocellular carcinoma.

The firm is continuing a Phase I study of its lead SMARCA4 inhibitor and will advance its CBP and selective EP300 degrader programs into the clinic in 2026.

The agency outlined the adjustments it's willing to make to "remove barriers and perceived misconceptions" for innovative medicines.

The firm expects its $1.25 billion cash runway to cover operating and capital expenses through 2029, including development plans for key assets.

The company will use the funds to advance its drug design platform and lead program in EGFR-expressing solid tumors and expand globally.